Cerevel (CERE) - Market Cap to Earnings

Symbol and logo of brand Cerevel Therapeutics Inc (CERE)

Cerevel Therapeutics (CERE) development in neuromedicine is complicated by global conflicts affecting patent law and reagent supplies. This price chart on GURU.Markets confirms this, recording the indicator at -17.80. Cerevel Therapeutics (CERE) relies on external contractors for drug synthesis to minimize costs. Meanwhile, support from a powerful medical behemoth has ensured financial stability and the uninterrupted development of scientific research.

Cerevel (CERE) - P/E Multiple from 07/04/2022 to 08/10/2024

Comprehensive metric breakdowns and analytics for Cerevel Therapeutics Inc (CERE)

- market capitalization indicators:
Comprehensive company analysis:Cerevel
Brand item of Cerevel Therapeutics, Inc.

Cerevel Therapeutics specializes in developing innovative therapies for severe central nervous system disorders. Analyzing the company's price-to-earnings ratio, an investor sees the current value of -17.80. This coefficient determines the payback period of the capitalization based on the generated net income. The metric's dynamics allow for an assessment of the market revaluation of biotech assets during periods of volatility. This helps determine the issuer's margin of safety relative to the industry benchmark.

Competing companies

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea|Price to Earnings Multiple CRGT (Cortigent)|Price to Earnings Ratio Avenue Therapeutics (ATXI)|BCLI - Market Cap to Earnings|P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Price to Earnings Ratio|ELYM: Price to Earnings Ratio|Business Payback Period Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Price to Earnings Ratio|Marinus - Company Value to Net Income|Price to Earnings Ratio NKGen Biotech Inc|NRBO: Company Value to Net Income|Price to Earnings Ratio SAGE (Sage Therapeutics, Inc.)|Business Payback Period Neurotrope|Price to Earnings Ratio Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Market Cap to Earnings|WENA: Price to Earnings Ratio